This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
December 16, 2021
Nordic Nanovector appoints Experienced International Life Sciences Executive Sandra Jonsson as Chief Operating Officer
December 15, 2021
Targovax awarded NOK 9.8m research grant by the Research Council of Norway towards the TG mutant RAS program
December 15, 2021
Doctrin makes strategic recruitments to support further expansion – Jesper Eriksson joins as new CFO and Michael Ekelund as CCO
December 15, 2021
Targovax ASA – Final results of the rights issue
December 14, 2021
HelloBetter Diabetes and Depression – new therapy option for psychologically stressed people with diabetes now available on prescription
December 14, 2021
Recap and Update of Positive Data from Three Presentations in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Presented at the 2021 American Society of Hematology (ASH) Annual Meeting
December 13, 2021
Aprea Therapeutics Presents Primary Analysis from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML at the 2021 American Society of Hematology (ASH) Annual Meeting
December 10, 2021
Oncopeptides presents new melflufen data at the Annual American Society of Hematology Meeting ASH
December 09, 2021
Aprea Therapeutics Announces Removal of FDA Clinical Hold on Eprenetapopt in Lymphoid Malignancies
December 06, 2021
Carisma Therapeutics Announces Collaboration with Merck to Evaluate CAR-Macrophages in Combination with KEYTRUDA® (pembrolizumab) in a Clinical Study